+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease

An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease

Cancer 95(12): 2534-2538

The relative importance of prognostic factors in patients with early-stage Hodgkin disease remains controversial. The purpose of this study was to evaluate prognostic factors among patients who received chemotherapy before radiotherapy. From 1987 to 1995, 217 consecutive patients ranging in age from 16 to 88 years (median, 28 years) with Ann Arbor Stage I (n = 55) or II (n = 162) Hodgkin disease underwent chemotherapy before radiotherapy at a single center. Most were treated on prospective studies. Patients received a median of three cycles of induction chemotherapy. Mitoxantrone, vincristine, vinblastine, and prednisone (NOVP), doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), cyclophosphamide, vinblastine, procarbazine, prednisone, doxorubicin, bleomycin, dacarbazine, and CCNU (CVPP/ABDIC), or other chemotherapeutic regimens were given to 160, 18, 15, 10, and 14 patients, respectively. The median radiotherapy dose was 40 Gy. Serum beta-2-microglobulin (beta-2M) levels ranged from 1.0 to 4.1 mg/L (median, 1.7 mg/L; upper limit of normal, 2.0 mg/L). We studied univariate and multivariate associations between survival and the following clinical features: serum beta-2M level above 1.25 times the upper limit of normal (n = 12), male gender (n = 113), hypoalbuminemia (n = 11), and bulky mediastinal disease (n = 94). Follow-up of surviving patients ranged from 0.9 to 13.4 years (median, 6.6 years) and 92% were observed for 3.0 or more years. Nineteen patients have died. Only elevation of the serum beta-2M level was an independent adverse prognostic factor for overall survival (P = 0.0009). The prognostic significance of a simple, widely available, and inexpensive blood test, beta-2M, has not been studied routinely in patients with Hodgkin disease and should be tested prospectively in large, cooperative group trials.

(PDF emailed within 0-6 h: $19.90)

Accession: 010158761

Download citation: RISBibTeXText

PMID: 12467067

DOI: 10.1002/cncr.10998

Related references

Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leukemia and Lymphoma 49(11): 2091-2098, 2008

Elevated serum IL-10 An adverse prognostic factor for failure-free survival in adults with advanced Hodgkins disease. Blood 88(10 SUPPL 1 PART 1-2): 226A, 1996

Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. Journal of Clinical Oncology 11(6): 1108-1111, 1993

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget 7(44): 72219-72228, 2016

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. Medical Oncology 31(9): 185, 2015

Elevated Serum Level of YLK-40 Is an Independent Prognostic Factor for Poor Survival in Patients with Metastatic Melanoma. Yearbook of Dermatology and Dermatologic Surgery 2007: 358-359, 2007

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5): 1130-1139, 2006

Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma. Oncology 87(1): 40-47, 2014

Sedimentation rate esr as predictive factor for early relapse er and survival in 772 eortc patients with early stage cs i ii hodgkin disease hd. Clinical & Investigative Medicine 12(SUPPL 4): B46, 1989

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group. Annals of Oncology 11(5): 617-623, 2000

The serum beta-2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia. Blood 86(10 SUPPL 1): 606A, 1995

Elevated serum beta-2-microglobulin--a prognostic marker for development of AIDS among patients with persistent generalized lymphadenopathy. Infection 16(2): 109-110, 1988

Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. European Journal of Haematology 76(1): 51-57, 2005

The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients. Terapevticheskii Arkhiv 68(10): 28-31, 1996

Beta-2 microglobulin Predictive prognostic factor for response and survival in Hodgkins disease of young adults. Nouvelle Revue Francaise d'Hematologie 35(3): 361, 1993